# A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

> **NCT05864391** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 40 (actual)

## Conditions studied

- Steatohepatitis

## Interventions

- **DRUG:** AZD7503

## Key facts

- **NCT ID:** NCT05864391
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-31
- **Primary completion:** 2024-03-20
- **Final completion:** 2024-03-20
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** AstraZeneca have decided to not move forward with the development of the compound.
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05864391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05864391, "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05864391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*